StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Zevra Therapeutics's pe ratio was 12.7× on Nov 11, 2026, against 17.9× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202612.7×−6.3
2025Dec 31, 202519.1×–

More Zevra Therapeutics figures

See a number that looks wrong?